北京阳光诺和药物研究股份有限公司关于公司诉讼结果的公告

Core Viewpoint - The company, Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd., has received a first-instance judgment in a lawsuit against Hunan Hengsheng Pharmaceutical Co., Ltd. for unpaid research fees totaling 620,000 yuan, along with overdue payment penalties [1][3] Group 1: Lawsuit Overview - The lawsuit pertains to Hunan Hengsheng's overdue payments for research fees related to 24 products, including "Ambroxol Hydrochloride Injection" and "Clindamycin Phosphate Injection" [2] - The court has ordered Hunan Hengsheng to pay the principal amount of 620,000 yuan and additional penalties calculated at a 5% annual interest rate from specified dates [3] Group 2: Financial Impact - The company has proactively accounted for the receivables from Hunan Hengsheng by fully provisioning for bad debts, indicating that the lawsuit will not negatively impact the company's current or future profits [1][3] - The final execution of the judgment remains uncertain as the case is still within the appeal period, and the actual impact will depend on the enforcement of the judgment [3]